
Virtual Meeting to be held on November 10 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ODTX | Odyssey Therapeutics, Inc. | 19.31 | 2.93 | 17.90% |
| Name | Price | % Change | |
|---|---|---|---|
| $19.31 | +17.90% |

Virtual Meeting to be held on November 10 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot

Odyssey Therapeutics (ODTX) announced the publication of a research paper titled “TNFR2 agonism increases tissue and effector Treg cells” in The Journal of Immunology. The findings demonstrate that tumor necrosis

H.C. Wainwright assumed coverage of Odyssey Therapeutics (ODTX) with a Buy rating and $40 price target The firm says the investment case is concentrated in OD-001, an oral, allosteric inhibitor

Odyssey Therapeutics, Inc. ($ODTX) announced an update on their ongoing clinical study. Study Overview: Odyssey Therapeutics, Inc. is evaluating how the investigational drug OD-001 moves through the body in healthy

Odyssey Therapeutics (ODTX) announced results from the completed induction period of its Phase 2a clinical trial evaluating OD-001, an oral, selective RIPK2 scaffolding inhibitor, in patients with moderate-to-severe ulcerative colitis,

UBS initiated coverage of Odyssey Therapeutics (ODTX) with a Buy rating and $27 price target The firm views the company’s OD-001, a novel oral RIPK2 inhibitor, as a promising new

Raymond James initiated coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and $42 price target Odyssey’s lead asset OD-001 is in Phase 2 development for inflammatory bowel diseases, including

H.C. Wainwright says Beeline Medicines’ Phase 2 success of afimetoran in systemic lupus erythematosus increases the firm’s confidence in Odyssey Therapeutics (ODTX)’ OD-002. The Beeline trial success in systemic lupus

H.C. Wainwright analyst Emily Bodnar initiated coverage of Odyssey Therapeutics (ODTX) with a Buy rating and $44 price target The company is developing precision small molecules and protein therapeutics against

Evotec (EVO) announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics (ODTX) to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreement, Odyssey will
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.